Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
39
Not yet recruiting, industry sponsors, Infectious disease and vaccines, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,960
39 trials
Showing 1 to 25, recently updated first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07862569 · 45 participants (planned) · Start Dec 23, 2026 · Primary completion Sep 24, 2029
Drug: DOR/ISL · For: HIV-1; HIV Infection
Sites: Tampa, Florida; The Bronx, New York
- A Study of SL-325 in Participants With Hidradenitis SuppurativaPivotal-lookingNot yet recruiting
Shattuck Labs, Inc.Industry
NCT07934017 · 150 participants (planned) · Start Jan 2027 · Primary completion Feb 2028
Drug: SL-325; Placebo · For: Hidradenitis Suppurativa (HS)
- Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide AnaloguesPivotal-lookingNot yet recruiting
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.Industry
NCT07933627 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Mar 20, 2027
Drug: YKYY013; YKYY013 Placebo · For: HBV (Hepatitis B Virus)
Sites: Beijing, China
Sinfatin S.LIndustry
NCT07930637 · 80 participants (planned) · Start Nov 6, 2026 · Primary completion Mar 2028
Drug: Rimonabant; Placebo · For: Post-COVID-19 Syndrome
Sites: San Sebastián, Spain; Albacete, Spain; Madrid, Spain · 4 sites in all
- Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual OnychomycosisPivotal-lookingNot yet recruiting
SATO Pharmaceutical Co., Ltd.Industry
NCT07929844 · 204 participants (planned) · Start Nov 24, 2026 · Primary completion Sep 23, 2028
Drug: SKX-16 (Luliconazole 10% Solution); Vehicle solution · For: Onychomycosis of Toenails
Sites: Los Angeles, California; San Francisco, California; Miami, Florida · 6 sites in all
- A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07917910 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 30, 2028
Drug: HT-101 + HT-102; HT-101 placebo + HT-102 placebo · For: Chronic Hepatitis B Virus Infection
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Hangzhou) Co., Ltd.Industry
NCT07897448 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; TVAX-008 and 2 more · For: Chronic Hepatitis B
- Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromePivotal-lookingNot yet recruiting
Invivyd, Inc.Industry
NCT07899346 · 130 participants (planned) · Start Oct 2026 · Primary completion Jun 2027
Drug: VYD2311; Placebo · For: Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine and 1 more
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsNot yet recruiting
Medsyn Biopharma, LLCIndustry
NCT07899632 · 75 participants (planned) · Start Nov 2026 · Primary completion Aug 2029
Drug: MDSY-1240 · For: Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic and 11 more
- WST03 Capsule Combined With Metronidazole for Bacterial VaginosisPivotal-lookingNot yet recruiting
SPH Sine Pharmaceutical Laboratories Co., Ltd.Industry
NCT07888699 · 150 participants (planned) · Start Oct 20, 2026 · Primary completion Oct 15, 2027
Drug: High-dose WST03 Vaginal Capsule Metronidazole; Low-dose WST03 Vaginal Capsule Metronidazole and 1 more · For: Bacterial Vaginosis (BV)
Sites: Beijing, China; Chongqing, China; Shenzhen, China · 14 sites in all
- Prevention of COVID-19 Infection to Severe Pneumonia or ARDSNot yet recruiting
Enzychem Lifesciences CorporationIndustry
NCT04569227 · 60 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2027
Drug: EC-18; Placebo · For: Covid19 Pneumonia
Sites: The Bronx, New York; Warwick, Rhode Island
- Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.Not yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT07881991 · 80 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 31, 2027
Drug: SYH2066; Placebo · For: Respiratory Syncytial Virus Infections
Sites: Beijing, China
- A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular EventsPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07712380 · 450 participants (planned) · Start Oct 23, 2026 · Primary completion May 2, 2029
Drug: Adjuvanted RSVPreF3 vaccine · For: Cardiovascular Disease
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Ausper Biopharma Co., Ltd.Industry
NCT07876856 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; Placebo and 1 more · For: Chronic Hepatitis B
F2G LtdIndustry
NCT07712484 · 50 participants (planned) · Start Dec 2026 · Primary completion Jun 2028
Drug: Olorofim; Placebo · For: Coccidioidomycosis; Disseminated Fungal Infection; Coccidioides Infection and 5 more
- A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)Pivotal-lookingNot yet recruiting
ViiV HealthcareGSK (GSK)
NCT07816250 · 200 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 10, 2032
Drug: VH4011499; CAB and 1 more · For: HIV Infections
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation SolutionPivotal-lookingNot yet recruiting
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.Industry
NCT07808268 · 160 participants (planned) · Start Oct 10, 2026 · Primary completion Dec 10, 2027
Drug: YKYY018 for Inhalation Solution; YKYY018 Placebo · For: Respiratory Syncytial Virus (RSV)
Sites: Beijing, China
- A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.Pivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07798193 · 213 participants (planned) · Start Oct 10, 2026 · Primary completion Apr 30, 2027
Drug: SYH2085; Placebo · For: Influenza
- Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected AdultsPivotal-lookingNot yet recruiting
Worcester HIV VaccineIndustry
NCT07675629 · 126 participants (planned) · Start Sep 1, 2026 · Primary completion Aug 31, 2028
Drug: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)); PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)) and 3 more · For: HIV Prevention
Sites: Boston, Massachusetts; Cape Town, South Africa
- Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 SymptomsNot yet recruiting
Kimera Labs Inc.Industry
NCT07664696 · 64 participants (planned) · Start Jan 2027 · Primary completion Jun 2028
Drug: IV infusion using an isolated, placental, mesenchymal stem cell derived EVs; Placebo IV administration · For: COVID-19
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVIDPivotal-lookingNot yet recruiting
HealthBio, Inc.Industry
NCT06974084 · 252 participants (planned) · Start Jul 15, 2026 · Primary completion Dec 1, 2026
Drug: Maraviroc (MVC); Atorvastatin, 10mg, 20mg, 40mg and 2 more · For: Long COVID
Sites: Tucson, Arizona
- A Study of VG712 in Patients With Mycosis FungoidesPivotal-lookingNot yet recruiting
Virogen Biotechnology Inc.Industry
NCT07529405 · 386 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 30, 2030
Drug: VG712; Mogamulizumab · For: Mycosis Fungoides
Sites: Tampa, Florida
- Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelPivotal-lookingNot yet recruiting
Traws Pharma, Inc.Industry
NCT07503405 · 165 participants (planned) · Start Jun 2026 · Primary completion Nov 2026
Drug: TRX-100; Placebo and 1 more · For: Influenza
Sites: London, United Kingdom
- Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV PatientsNot yet recruiting
Chengdu Syncor Pharmaceutical Co., Ltd.Industry
NCT07483671 · 80 participants (planned) · Start Apr 15, 2026 · Primary completion Jan 24, 2027
Drug: BPR-101 capsules:Investigational product for the treatment of BV · For: Bacterial Vaginosis
Sites: Tianjin, China
BioVersys AGIndustry
NCT07350174 · 64 participants (planned) · Start Mar 30, 2026 · Primary completion Mar 30, 2028
Drug: HRZE; HRZE plus Alpe375 and 2 more · For: Tuberculosis Meningitis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.